F M Placenza1, H Rajabi, J Stewart. 1. Center for Studies in Behavioral Neurobiology/Groupe de Recherche en Neurobiologie Comportementale, Concordia University, 7141 Sherbrooke Street West, Montreal, Quebec H4B 1R6, Canada. fplacenza@utsc.utoronto.ca
Abstract
RATIONALE: Chronic treatment with the mu-opioid receptor agonist, buprenorphine, reduces cocaine-induced behaviors in rats with a history of cocaine self-administration. The mechanisms underlying these actions of buprenorphine remain unclear. OBJECTIVES: The objective of this study is to investigate the effects of chronic buprenorphine treatment on cocaine-induced activity and levels of glutamate and dopamine (DA) in the nucleus accumbens (NAc) in rats that were preexposed to cocaine or drug-naïve. MATERIALS AND METHODS: In experiment 1, basal levels of NAc glutamate were assessed using in vivo microdialysis in cocaine-naïve rats that were treated chronically with buprenorphine (3.0 mg/kg per day) via osmotic minipumps or that underwent sham surgery. In experiment 2, rats were preexposed to seven daily injections of cocaine or saline. After a 12-16-day drug-free period, extracellular levels of NAc glutamate and DA and locomotor activity were assessed simultaneously, before and after an acute injection of cocaine (15 mg/kg, intraperitoneal), in rats under sham and chronic buprenorphine (3.0 mg/kg per day) treatment. RESULTS: Chronic buprenorphine treatment increased basal levels of glutamate in drug-naïve and cocaine-preexposed rats, blocked the expression of locomotor sensitization to cocaine, and potentiated the NAc DA response to acute cocaine in cocaine-preexposed rats. CONCLUSIONS: These findings suggest that buprenorphine may block the expression of cocaine sensitization and other cocaine-related behaviors by increasing basal levels of glutamate in the NAc, which would serve to decrease the effectiveness of cocaine or cocaine-associated cues.
RATIONALE: Chronic treatment with the mu-opioid receptor agonist, buprenorphine, reduces cocaine-induced behaviors in rats with a history of cocaine self-administration. The mechanisms underlying these actions of buprenorphine remain unclear. OBJECTIVES: The objective of this study is to investigate the effects of chronic buprenorphine treatment on cocaine-induced activity and levels of glutamate and dopamine (DA) in the nucleus accumbens (NAc) in rats that were preexposed to cocaine or drug-naïve. MATERIALS AND METHODS: In experiment 1, basal levels of NAc glutamate were assessed using in vivo microdialysis in cocaine-naïve rats that were treated chronically with buprenorphine (3.0 mg/kg per day) via osmotic minipumps or that underwent sham surgery. In experiment 2, rats were preexposed to seven daily injections of cocaine or saline. After a 12-16-day drug-free period, extracellular levels of NAc glutamate and DA and locomotor activity were assessed simultaneously, before and after an acute injection of cocaine (15 mg/kg, intraperitoneal), in rats under sham and chronic buprenorphine (3.0 mg/kg per day) treatment. RESULTS: Chronic buprenorphine treatment increased basal levels of glutamate in drug-naïve and cocaine-preexposed rats, blocked the expression of locomotor sensitization to cocaine, and potentiated the NAc DA response to acute cocaine in cocaine-preexposed rats. CONCLUSIONS: These findings suggest that buprenorphine may block the expression of cocaine sensitization and other cocaine-related behaviors by increasing basal levels of glutamate in the NAc, which would serve to decrease the effectiveness of cocaine or cocaine-associated cues.
Authors: David A Baker; Krista McFarland; Russell W Lake; Hui Shen; Xing-Chun Tang; Shigenobu Toda; Peter W Kalivas Journal: Nat Neurosci Date: 2003-07 Impact factor: 24.884
Authors: Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll Journal: J Pharmacol Exp Ther Date: 2010-12-21 Impact factor: 4.030
Authors: Peter R Kufahl; Natalie A Peartree; Krista L Heintzelman; Maggie Chung; Janet L Neisewander Journal: Brain Res Date: 2014-10-22 Impact factor: 3.252
Authors: Bruno G Berardino; Estefanía A Fesser; Laura M Belluscio; Octavio Gianatiempo; Nicolás Pregi; Eduardo T Cánepa Journal: Psychopharmacology (Berl) Date: 2019-07-06 Impact factor: 4.530
Authors: Annie Umbricht; Anthony DeFulio; Erin L Winstanley; D Andrew Tompkins; Jessica Peirce; Miriam Z Mintzer; Eric C Strain; George E Bigelow Journal: Drug Alcohol Depend Date: 2014-04-16 Impact factor: 4.492